Prosecution Insights
Last updated: August 18, 2026
Application No. 18/564,245

AZEOTROPIC OR QUASI-AZEOTROPIC COMPOSITION COMPRISING CHLOROTRIFLUOROETHYLENE AND/OR 1,1,2-TRIFLUOROETHANE

Non-Final OA §102
Filed
Nov 27, 2023
Priority
Jun 07, 2021 — FR FR2105961 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
Tech Center
Assignee
Arkema France
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
895 granted / 1162 resolved
+17.0% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
74 currently pending
Career history
1227
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
30.4%
-9.6% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1162 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 10-18 are pending. Election/Restrictions Applicant's election without traverse of Group I, claims 10-14, and the species of 1,1,1,2-tetrafluoroethane, in the reply filed on 07/16/2026 is acknowledged. The election was made without traverse. The requirement is therefore made FINAL. Claims 15-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Composition with additional compound elected species 1,1,1,2-tetrafluoroethane is free of prior art and the search is extended to other additional compounds of claim 12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Claims 10-14 are under current examination. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 10-14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Asahi (CN105753634; as provided by the applicant on IDs dated 11/27/2023). Asahi discloses an azeotropic composition comprising chlorotrifluoroethylene (CFO1113) (such as in amount 90%, 86%, 84%, 76% etc.,) 1,1,2-trifluoroethane (HFC-143) (10%, 14%, 16%, 24%) (reads on compositions of 10, 11, 13 and 14 with respect to at most 20% of 1,12-trifluoroethane and at most 50% by weight of 1,1-difluoroethane) with boiling point between -5 to +20C at a pressure of ~1x105 pa (=1 bar, same as in the instant claim 11) with or without other fluorine containing compounds (entire prior art, especially tables and examples). The cited prior art discloses that the composition may contain other fluorine containing compounds with examples of 1-chloro-1,1,2-trifluoroethane (HCFC-133b) (entire prior art, especially tables and examples; for instance, example 1). The cited prior art further discloses that amounts of chlorotrifluoroethylene (CFO1113) and 1,1,2-trifluoroethane (HFC-143) may be adjusted. Since the cited prior art reads on all the limitations of the instant claims 10-14, these claims are anticipated. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Nov 27, 2023
Application Filed
Jul 30, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702712
ENTEROENDOCRINE CELL-TARGETING POLYMER SUBSTANCE CONJUGATED WITH PHOTOSENSITIZER, AND MEDICAL USE THEREOF FOR AMELIORATING METABOLIC DISEASE
3y 8m to grant Granted Aug 11, 2026
Patent 12697349
COMPOSITIONS AND METHODS FOR TREATING RAS-MUTANT CANCERS
4y 9m to grant Granted Aug 04, 2026
Patent 12698300
RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST
3y 3m to grant Granted Aug 04, 2026
Patent 12673127
LIQUID EMBOLIC MATERIAL COMPOSITION
4y 1m to grant Granted Jul 07, 2026
Patent 12673965
RAW MATERIAL FOR CHEMICAL DEPOSITION CONTAINING ORGANORUTHENIUM COMPOUND, AND CHEMICAL DEPOSITION METHOD USING THE RAW MATERIAL FOR CHEMICAL DEPOSITION
3y 11m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.2%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1162 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month